This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Tenet Healthcare (THC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Tenet Healthcare (THC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tenet Healthcare (THC) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Tenet Healthcare (THC) stood at $102.18, denoting a +1.46% change from the preceding trading day.
Tenet Healthcare (THC) Soars 76% in a Year: What Lies Ahead?
by Zacks Equity Research
Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.
Should You Invest in Tenet (THC) Based on Bullish Wall Street Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Tenet (THC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Tenet (THC) Divests Six Hospitals, Sustains Divestiture Spree
by Zacks Equity Research
Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Tenet Healthcare (THC) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Tenet Healthcare (THC) closed at $102.05, indicating a -1.12% shift from the previous trading day.
Community Health Systems (CYH) Up 17.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Community Health Systems (CYH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tenet Healthcare (THC) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Tenet Healthcare (THC) closed the most recent trading day at $100.38, moving +0.42% from the previous trading session.
Why the Market Dipped But Tenet Healthcare (THC) Gained Today
by Zacks Equity Research
Tenet Healthcare (THC) closed the most recent trading day at $95.56, moving +1.99% from the previous trading session.
Zacks Industry Outlook Highlights HCA Healthcare, Universal Health Services and Tenet Healthcare
by Zacks Equity Research
HCA Healthcare, Universal Health Services and Tenet Healthcare have been highlighted in this Industry Outlook article.
3 Stocks Worth a Deeper Dive in the Thriving Hospital Industry
by Kaibalya Pravo Dey
Following a careful analysis of the Zacks Medical-Hospital industry, we advise focusing on companies like HCA, UHS and THC.
Tenet Healthcare (THC) to Sell Hospitals to Refine Portfolio
by Zacks Equity Research
Tenet Healthcare (THC) enters an agreement with Adventist Health to divest two of THC's hospitals, and continue to make Conifer's revenue cycle management services available for the divested operations.
Tenet Healthcare (THC) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Tenet Healthcare (THC) concluded the recent trading session at $89.22, signifying a -1.12% move from its prior day's close.
Brookdale Senior's (BKD) Q4 Loss Widens, Shares Drop 13%
by Zacks Equity Research
Brookdale Senior's (BKD) Q4 results were hit by inflationary challenges, an increase in facility operating lease expense and higher income tax provision. It expects adjusted EBITDA within $90-$95 million in first-quarter 2024.
Teladoc Health (TDOC) Q4 Loss Narrows on Lower Expenses
by Zacks Equity Research
Teladoc Health's (TDOC) Q4 results were aided by strong contributions from the Integrated Care unit and a decline in restructuring costs. Management targets adjusted EBITDA at a minimum of $425 million in 2025.
Tenet Healthcare (THC) Q4 Earnings Beat on Hospital Operations
by Zacks Equity Research
Tenet Healthcare (THC) expects net operating revenues to be between $19.9 billion and $20.3 billion in 2024.
Compared to Estimates, Tenet (THC) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Tenet (THC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?
by Zacks Equity Research
Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.
Gear Up for Tenet (THC) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Tenet (THC) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Strength Seen in Tenet (THC): Can Its 7.7% Jump Turn into More Strength?
by Zacks Equity Research
Tenet (THC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tenet Healthcare (THC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.